CN101019019A - 表面强化的光谱学活性复合纳米颗粒 - Google Patents
表面强化的光谱学活性复合纳米颗粒 Download PDFInfo
- Publication number
- CN101019019A CN101019019A CNA2005800159820A CN200580015982A CN101019019A CN 101019019 A CN101019019 A CN 101019019A CN A2005800159820 A CNA2005800159820 A CN A2005800159820A CN 200580015982 A CN200580015982 A CN 200580015982A CN 101019019 A CN101019019 A CN 101019019A
- Authority
- CN
- China
- Prior art keywords
- sacn
- particle
- nano particle
- described method
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims description 142
- 239000002131 composite material Substances 0.000 title description 8
- 239000002245 particle Substances 0.000 claims abstract description 111
- 238000000034 method Methods 0.000 claims description 229
- 239000000523 sample Substances 0.000 claims description 95
- 210000004027 cell Anatomy 0.000 claims description 90
- 238000001069 Raman spectroscopy Methods 0.000 claims description 81
- 239000000463 material Substances 0.000 claims description 72
- 229910052751 metal Inorganic materials 0.000 claims description 59
- 239000002184 metal Substances 0.000 claims description 59
- 238000002360 preparation method Methods 0.000 claims description 58
- 238000001228 spectrum Methods 0.000 claims description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- 239000012491 analyte Substances 0.000 claims description 46
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 claims description 44
- 210000001519 tissue Anatomy 0.000 claims description 35
- 238000001237 Raman spectrum Methods 0.000 claims description 34
- 239000002082 metal nanoparticle Substances 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 32
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 31
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 239000003153 chemical reaction reagent Substances 0.000 claims description 24
- 238000012856 packing Methods 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 21
- 238000004070 electrodeposition Methods 0.000 claims description 18
- 230000001575 pathological effect Effects 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 18
- 239000010420 shell particle Substances 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 16
- 238000000151 deposition Methods 0.000 claims description 15
- 230000008021 deposition Effects 0.000 claims description 15
- 239000011258 core-shell material Substances 0.000 claims description 13
- 230000003287 optical effect Effects 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 238000007747 plating Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 238000001311 chemical methods and process Methods 0.000 claims description 10
- 238000004043 dyeing Methods 0.000 claims description 10
- 230000005611 electricity Effects 0.000 claims description 10
- 230000005284 excitation Effects 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 230000008676 import Effects 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 239000004973 liquid crystal related substance Substances 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 3
- 241001455273 Tetrapoda Species 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 238000010306 acid treatment Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 210000000746 body region Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003722 extracellular fluid Anatomy 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000005075 mammary gland Anatomy 0.000 claims description 3
- 208000026435 phlegm Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000012632 fluorescent imaging Methods 0.000 claims description 2
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000011002 quantification Methods 0.000 abstract description 2
- 239000010931 gold Substances 0.000 description 97
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 239000000243 solution Substances 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 27
- 239000002073 nanorod Substances 0.000 description 27
- 229910052737 gold Inorganic materials 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 22
- 229940098773 bovine serum albumin Drugs 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 239000000084 colloidal system Substances 0.000 description 21
- 238000003384 imaging method Methods 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 229910052709 silver Inorganic materials 0.000 description 16
- FHTDDANQIMVWKZ-UHFFFAOYSA-N 1h-pyridine-4-thione Chemical compound SC1=CC=NC=C1 FHTDDANQIMVWKZ-UHFFFAOYSA-N 0.000 description 15
- 108010090804 Streptavidin Proteins 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- -1 4-pyridine radicals Chemical class 0.000 description 14
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 14
- 239000011521 glass Substances 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000000975 dye Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000009871 nonspecific binding Effects 0.000 description 13
- 239000002096 quantum dot Substances 0.000 description 13
- 235000020958 biotin Nutrition 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 108010087904 neutravidin Proteins 0.000 description 12
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 229960002685 biotin Drugs 0.000 description 11
- 239000011616 biotin Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 238000005457 optimization Methods 0.000 description 11
- 230000003595 spectral effect Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- BXAVKNRWVKUTLY-UHFFFAOYSA-N 4-sulfanylphenol Chemical compound OC1=CC=C(S)C=C1 BXAVKNRWVKUTLY-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000009713 electroplating Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 8
- 102100038358 Prostate-specific antigen Human genes 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000007599 discharging Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000001465 metallisation Methods 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- 125000006850 spacer group Chemical group 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- 108010044434 Alpha-methylacyl-CoA racemase Proteins 0.000 description 6
- 102100040410 Alpha-methylacyl-CoA racemase Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000006287 biotinylation Effects 0.000 description 6
- 238000007413 biotinylation Methods 0.000 description 6
- HNNSUZPWERIYIL-UHFFFAOYSA-N chembl1730100 Chemical compound O1CC2(O)CC3=CC(O)=C(O)C=C3C2=C2C1=C(O)C(=O)C=C2 HNNSUZPWERIYIL-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 238000003917 TEM image Methods 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 150000004756 silanes Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 238000009415 formwork Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000010695 polyglycol Substances 0.000 description 4
- 229920000151 polyglycol Polymers 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000000479 surface-enhanced Raman spectrum Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000012099 Alexa Fluor family Substances 0.000 description 3
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000007421 fluorometric assay Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000013528 metallic particle Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000001845 vibrational spectrum Methods 0.000 description 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N 2,3,5-trimethylpyridine Chemical compound CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 241000819038 Chichester Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 241000692870 Inachis io Species 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 238000005275 alloying Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002527 isonitriles Chemical class 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-PTQBSOBMSA-N pyridine-15n Chemical compound C1=CC=[15N]C=C1 JUJWROOIHBZHMG-PTQBSOBMSA-N 0.000 description 2
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 2
- 239000010944 silver (metal) Substances 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- YUYCVXFAYWRXLS-UHFFFAOYSA-N trimethoxysilane Chemical compound CO[SiH](OC)OC YUYCVXFAYWRXLS-UHFFFAOYSA-N 0.000 description 2
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- QZRAABPTWGFNIU-UHFFFAOYSA-N 3-[dimethyl(octyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O QZRAABPTWGFNIU-UHFFFAOYSA-N 0.000 description 1
- KVUMYOWDFZAGPN-UHFFFAOYSA-N 3-trimethoxysilylpropanenitrile Chemical compound CO[Si](OC)(OC)CCC#N KVUMYOWDFZAGPN-UHFFFAOYSA-N 0.000 description 1
- MWVTWFVJZLCBMC-UHFFFAOYSA-N 4,4'-bipyridine Chemical compound C1=NC=CC(C=2C=CN=CC=2)=C1 MWVTWFVJZLCBMC-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 229910000967 As alloy Inorganic materials 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- SMVQTJSDCKKODW-UHFFFAOYSA-N CO[SiH](OC)OC.N1=CC=CC=C1 Chemical compound CO[SiH](OC)OC.N1=CC=CC=C1 SMVQTJSDCKKODW-UHFFFAOYSA-N 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000872580 Homo sapiens Serine protease hepsin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000961787 Josa Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000669618 Nothes Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102100034801 Serine protease hepsin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- KZNMRPQBBZBTSW-UHFFFAOYSA-N [Au]=O Chemical compound [Au]=O KZNMRPQBBZBTSW-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910000905 alloy phase Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 208000035405 autosomal recessive with axonal neuropathy spinocerebellar ataxia Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000001912 cyanamides Chemical class 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910001922 gold oxide Inorganic materials 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004425 isosulfocyanate group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 1
- 239000002078 nanoshell Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- NICDRCVJGXLKSF-UHFFFAOYSA-N nitric acid;trihydrochloride Chemical compound Cl.Cl.Cl.O[N+]([O-])=O NICDRCVJGXLKSF-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000010608 single channel array normalization Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D1/00—Electroforming
- C25D1/003—3D structures, e.g. superposed patterned layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/06—Scanning arrangements arrangements for order-selection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/02—Details
- G01J3/10—Arrangements of light sources specially adapted for spectrometry or colorimetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/44—Raman spectrometry; Scattering spectrometry ; Fluorescence spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/12—Generating the spectrum; Monochromators
- G01J2003/1213—Filters in general, e.g. dichroic, band
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J3/00—Spectrometry; Spectrophotometry; Monochromators; Measuring colours
- G01J3/28—Investigating the spectrum
- G01J3/2823—Imaging spectrometer
- G01J2003/2826—Multispectral imaging, e.g. filter imaging
Abstract
Description
Claims (48)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56509904P | 2004-04-23 | 2004-04-23 | |
US60/565,099 | 2004-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101019019A true CN101019019A (zh) | 2007-08-15 |
Family
ID=36647902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800159820A Pending CN101019019A (zh) | 2004-04-23 | 2005-04-25 | 表面强化的光谱学活性复合纳米颗粒 |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP3656735A1 (zh) |
JP (1) | JP2007534944A (zh) |
KR (2) | KR101230180B1 (zh) |
CN (1) | CN101019019A (zh) |
AU (1) | AU2005323511A1 (zh) |
BR (1) | BRPI0510116B1 (zh) |
CA (2) | CA2830663A1 (zh) |
DK (1) | DK1749122T3 (zh) |
ES (1) | ES2752457T3 (zh) |
MX (1) | MX300005B (zh) |
PL (1) | PL1749122T3 (zh) |
SG (4) | SG185329A1 (zh) |
WO (1) | WO2006073439A2 (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101178360B (zh) * | 2007-09-24 | 2010-12-15 | 重庆医科大学 | 基于积分球增强光散射检测技术的均相亲和分析新方法 |
CN102661943A (zh) * | 2012-04-25 | 2012-09-12 | 广西师范大学 | 用表面增强拉曼光谱测定胱氨酸的方法 |
CN102712464A (zh) * | 2009-09-18 | 2012-10-03 | 阿莫绿色技术有限公司 | 使用交流电电解制备金属纳米颗粒的方法和设备 |
CN103348234A (zh) * | 2011-02-09 | 2013-10-09 | 新日铁住金化学株式会社 | 金属微粒子分散复合物及其制造方法、以及产生局域表面等离子体共振的基板 |
CN103439246A (zh) * | 2013-09-03 | 2013-12-11 | 北京科技大学 | 一种基于模块化的多因素大气环境模拟试验装置及方法 |
CN103534577A (zh) * | 2011-04-05 | 2014-01-22 | 欧普图斯(苏州)光学纳米科技有限公司 | 基于纳米结构检测装置的检测网络 |
CN103718038A (zh) * | 2011-05-29 | 2014-04-09 | 韩国化学研究院 | 高速的基于拉曼分析的多药物高速筛选装置 |
CN104507871A (zh) * | 2012-05-31 | 2015-04-08 | 新加坡科技研究局 | 表面增强拉曼光谱(sers)标记偶联物及其制备方法 |
CN104937598A (zh) * | 2012-11-29 | 2015-09-23 | 霍夫曼-拉罗奇有限公司 | 靶向的测序读取值的准确且快速的定位 |
CN104940956A (zh) * | 2015-07-09 | 2015-09-30 | 中国科学院宁波材料技术与工程研究所 | 一种核壳结构的复合纳米材料及其制法和应用 |
CN107290324A (zh) * | 2016-04-12 | 2017-10-24 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种联用sers基底检测食品中激素的应用方法 |
CN108490063A (zh) * | 2018-04-13 | 2018-09-04 | 西北大学 | 一种生物硫醇电化学传感器及其制备方法与应用 |
CN109307669A (zh) * | 2017-07-28 | 2019-02-05 | 上海海洋大学 | 基于末端转移酶扩增核酸链制备核壳sers结构的方法 |
CN109540855A (zh) * | 2018-11-07 | 2019-03-29 | 沈阳化工大学 | 一种荧光金壳磁性椭球的制备方法 |
CN109612976A (zh) * | 2018-12-24 | 2019-04-12 | 北华大学 | 一种三维多层结构表面增强拉曼基底及其制备方法 |
CN110726705A (zh) * | 2019-10-25 | 2020-01-24 | 大连民族大学 | 一种基于贵金属/半导体调控的发光薄膜基底的荧光染料检测方法 |
CN111896522A (zh) * | 2020-08-24 | 2020-11-06 | 普识和康(杭州)科技有限公司 | 一种表面增强拉曼光谱检测基底及其应用 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7518721B2 (en) | 2005-09-09 | 2009-04-14 | Ge Homeland Protection, Inc. | Raman-active lateral flow device and methods of detection |
US7355703B2 (en) | 2005-09-09 | 2008-04-08 | Ge Homeland Protection, Inc. | Raman-active lateral flow device and methods of detection and making |
US20090155811A1 (en) * | 2006-01-27 | 2009-06-18 | Oxonica, Inc. | Lateral Flow Immunoassay With Encapsulated Detection Modality |
JP5151097B2 (ja) * | 2006-09-01 | 2013-02-27 | 株式会社リコー | 複合金属ナノ粒子、複合金属ナノ粒子を含む多光子吸収反応材料と反応生成物、複合金属ナノ粒子を含む多光子吸収反応助剤 |
AU2008228813C1 (en) | 2007-03-20 | 2015-01-22 | Becton, Dickinson And Company | Assays using surface-enhanced raman spectroscopy (SERS)-active particles |
ES2754814T3 (es) * | 2007-04-18 | 2020-04-20 | Sicpa Holding Sa | Ensayos de nanomarcadores de DRPS |
JP5057377B2 (ja) * | 2007-08-30 | 2012-10-24 | 国立大学法人埼玉大学 | 生体成分又はその機能の測定方法及び装置 |
CN102183535B (zh) * | 2011-03-11 | 2012-07-18 | 天津大学 | 基于sem图像的低维纳米材料识别方法 |
CN102323412B (zh) * | 2011-08-09 | 2014-01-01 | 中国科学院合肥物质科学研究院 | 一种拉曼编码微球的用途及利用拉曼编码微球检测肿瘤标志物的方法 |
WO2013059294A1 (en) * | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Methods and devices for detecting and separating target analyte species using anisotropic micro-particles |
DK2773958T3 (en) | 2011-11-02 | 2018-03-12 | Univ Cape Town | Method for identifying an analyte in a biological sample |
KR101494776B1 (ko) * | 2013-06-25 | 2015-02-23 | 국방과학연구소 | 미량 분석용 고감도 자극 반응성 표면증강 라만 산란 기판 제조 방법 및 그의 응용 |
US10577678B2 (en) | 2014-05-07 | 2020-03-03 | The Regents Of The University Of California | Fully alloyed AG—AU nanostructures |
CN112229828B (zh) * | 2020-08-11 | 2021-04-06 | 嘉兴学院 | 高选择性捕捉苏丹染料的sers活性基底及其制备方法 |
CN113221474B (zh) * | 2021-03-31 | 2022-08-23 | 深圳大学 | 考虑颗粒形状的cfd-dem模拟渗流侵蚀破坏的方法 |
CN114354464B (zh) * | 2021-12-22 | 2024-04-09 | 南京大学 | 一种对不同金属纳米颗粒高光谱库之间的相似性进行定量分析的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180415B1 (en) * | 1997-02-20 | 2001-01-30 | The Regents Of The University Of California | Plasmon resonant particles, methods and apparatus |
EP2295954B1 (en) * | 1999-10-06 | 2016-04-27 | Becton Dickinson and Company | Surface-enhanced spectroscopy-active composite nanoparticles |
WO2002079764A1 (en) * | 2001-01-26 | 2002-10-10 | Nanoplex Technologies, Inc. | Surface-enhanced spectroscopy-active sandwich nanoparticles |
US6748259B1 (en) * | 2000-06-15 | 2004-06-08 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
WO2003035829A2 (en) * | 2001-10-09 | 2003-05-01 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US20030211488A1 (en) * | 2002-05-07 | 2003-11-13 | Northwestern University | Nanoparticle probs with Raman spectrocopic fingerprints for analyte detection |
-
2005
- 2005-04-25 EP EP19191333.4A patent/EP3656735A1/en active Pending
- 2005-04-25 ES ES05856641T patent/ES2752457T3/es active Active
- 2005-04-25 DK DK05856641T patent/DK1749122T3/da active
- 2005-04-25 MX MXPA06012282 patent/MX300005B/es active IP Right Grant
- 2005-04-25 EP EP05856641.5A patent/EP1749122B1/en active Active
- 2005-04-25 KR KR1020067024549A patent/KR101230180B1/ko active IP Right Grant
- 2005-04-25 WO PCT/US2005/013989 patent/WO2006073439A2/en active Application Filing
- 2005-04-25 AU AU2005323511A patent/AU2005323511A1/en not_active Abandoned
- 2005-04-25 PL PL05856641T patent/PL1749122T3/pl unknown
- 2005-04-25 KR KR1020127013107A patent/KR20120058630A/ko not_active IP Right Cessation
- 2005-04-25 CA CA2830663A patent/CA2830663A1/en not_active Abandoned
- 2005-04-25 BR BRPI0510116-6A patent/BRPI0510116B1/pt active IP Right Grant
- 2005-04-25 SG SG2012078481A patent/SG185329A1/en unknown
- 2005-04-25 CN CNA2005800159820A patent/CN101019019A/zh active Pending
- 2005-04-25 SG SG2012078424A patent/SG185328A1/en unknown
- 2005-04-25 SG SG200902745-9A patent/SG152260A1/en unknown
- 2005-04-25 SG SG200902744-2A patent/SG152259A1/en unknown
- 2005-04-25 JP JP2007509703A patent/JP2007534944A/ja active Pending
- 2005-04-25 CA CA2563694A patent/CA2563694C/en active Active
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101178360B (zh) * | 2007-09-24 | 2010-12-15 | 重庆医科大学 | 基于积分球增强光散射检测技术的均相亲和分析新方法 |
CN102712464A (zh) * | 2009-09-18 | 2012-10-03 | 阿莫绿色技术有限公司 | 使用交流电电解制备金属纳米颗粒的方法和设备 |
CN102712464B (zh) * | 2009-09-18 | 2015-01-07 | 阿莫绿色技术有限公司 | 使用交流电电解制备金属纳米颗粒的方法和设备 |
CN103348234A (zh) * | 2011-02-09 | 2013-10-09 | 新日铁住金化学株式会社 | 金属微粒子分散复合物及其制造方法、以及产生局域表面等离子体共振的基板 |
CN103534577A (zh) * | 2011-04-05 | 2014-01-22 | 欧普图斯(苏州)光学纳米科技有限公司 | 基于纳米结构检测装置的检测网络 |
CN103534577B (zh) * | 2011-04-05 | 2016-12-07 | 欧普图斯(苏州)光学纳米科技有限公司 | 基于纳米结构检测装置的检测网络 |
CN103718038A (zh) * | 2011-05-29 | 2014-04-09 | 韩国化学研究院 | 高速的基于拉曼分析的多药物高速筛选装置 |
CN103718038B (zh) * | 2011-05-29 | 2016-06-22 | 韩国化学研究院 | 高速的基于拉曼分析的多药物高速筛选装置 |
CN102661943B (zh) * | 2012-04-25 | 2014-01-08 | 广西师范大学 | 用表面增强拉曼光谱测定胱氨酸的方法 |
CN102661943A (zh) * | 2012-04-25 | 2012-09-12 | 广西师范大学 | 用表面增强拉曼光谱测定胱氨酸的方法 |
CN104507871A (zh) * | 2012-05-31 | 2015-04-08 | 新加坡科技研究局 | 表面增强拉曼光谱(sers)标记偶联物及其制备方法 |
CN104507871B (zh) * | 2012-05-31 | 2017-11-10 | 新加坡科技研究局 | 表面增强拉曼光谱(sers)标记偶联物及其制备方法 |
CN104937598B (zh) * | 2012-11-29 | 2017-11-07 | 霍夫曼-拉罗奇有限公司 | 靶向的测序读取值的准确且快速的定位 |
US10127351B2 (en) | 2012-11-29 | 2018-11-13 | Roche Molecular Systems, Inc. | Accurate and fast mapping of reads to genome |
CN104937598A (zh) * | 2012-11-29 | 2015-09-23 | 霍夫曼-拉罗奇有限公司 | 靶向的测序读取值的准确且快速的定位 |
CN103439246B (zh) * | 2013-09-03 | 2016-04-20 | 北京科技大学 | 一种基于模块化的多因素大气环境模拟试验装置及方法 |
CN103439246A (zh) * | 2013-09-03 | 2013-12-11 | 北京科技大学 | 一种基于模块化的多因素大气环境模拟试验装置及方法 |
CN104940956A (zh) * | 2015-07-09 | 2015-09-30 | 中国科学院宁波材料技术与工程研究所 | 一种核壳结构的复合纳米材料及其制法和应用 |
CN104940956B (zh) * | 2015-07-09 | 2017-12-29 | 中国科学院宁波材料技术与工程研究所 | 一种核壳结构的复合纳米材料及其制法和应用 |
CN107290324A (zh) * | 2016-04-12 | 2017-10-24 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种联用sers基底检测食品中激素的应用方法 |
CN109307669A (zh) * | 2017-07-28 | 2019-02-05 | 上海海洋大学 | 基于末端转移酶扩增核酸链制备核壳sers结构的方法 |
CN108490063A (zh) * | 2018-04-13 | 2018-09-04 | 西北大学 | 一种生物硫醇电化学传感器及其制备方法与应用 |
CN108490063B (zh) * | 2018-04-13 | 2020-09-18 | 西北大学 | 一种生物硫醇电化学传感器及其制备方法与应用 |
CN109540855A (zh) * | 2018-11-07 | 2019-03-29 | 沈阳化工大学 | 一种荧光金壳磁性椭球的制备方法 |
CN109612976A (zh) * | 2018-12-24 | 2019-04-12 | 北华大学 | 一种三维多层结构表面增强拉曼基底及其制备方法 |
CN110726705A (zh) * | 2019-10-25 | 2020-01-24 | 大连民族大学 | 一种基于贵金属/半导体调控的发光薄膜基底的荧光染料检测方法 |
CN110726705B (zh) * | 2019-10-25 | 2022-07-22 | 大连民族大学 | 一种基于贵金属/半导体调控的发光薄膜基底的荧光染料检测方法 |
CN111896522A (zh) * | 2020-08-24 | 2020-11-06 | 普识和康(杭州)科技有限公司 | 一种表面增强拉曼光谱检测基底及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR101230180B1 (ko) | 2013-02-07 |
AU2005323511A1 (en) | 2006-07-13 |
SG152259A1 (en) | 2009-05-29 |
CA2830663A1 (en) | 2006-07-13 |
BRPI0510116A (pt) | 2007-09-25 |
JP2007534944A (ja) | 2007-11-29 |
SG152260A1 (en) | 2009-05-29 |
DK1749122T3 (da) | 2019-11-11 |
CA2563694C (en) | 2014-01-07 |
SG185329A1 (en) | 2012-11-29 |
EP1749122A2 (en) | 2007-02-07 |
KR20070064553A (ko) | 2007-06-21 |
EP3656735A1 (en) | 2020-05-27 |
CA2563694A1 (en) | 2006-07-13 |
KR20120058630A (ko) | 2012-06-07 |
MXPA06012282A (es) | 2007-04-30 |
SG185328A1 (en) | 2012-11-29 |
MX300005B (es) | 2012-06-07 |
EP1749122B1 (en) | 2019-08-14 |
EP1749122A4 (en) | 2008-05-28 |
WO2006073439A3 (en) | 2007-04-12 |
ES2752457T3 (es) | 2020-04-06 |
BRPI0510116B1 (pt) | 2020-11-03 |
WO2006073439A2 (en) | 2006-07-13 |
PL1749122T3 (pl) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101019019A (zh) | 表面强化的光谱学活性复合纳米颗粒 | |
US8497131B2 (en) | Surface enhanced spectroscopy-active composite nanoparticles comprising Raman-active reporter molecules | |
Pellas et al. | Gold nanorods for LSPR biosensing: synthesis, coating by silica, and bioanalytical applications | |
Jorge et al. | Optical fiber sensing using quantum dots | |
Kim et al. | Multiplexible wash-free immunoassay using colloidal assemblies of magnetic and photoluminescent nanoparticles | |
EP2040075A1 (en) | Compounds and markers for surface-enhanced raman scattering | |
US20070155021A1 (en) | Modification of metal nanoparticles for improved analyte detection by surface enhanced Raman spectroscopy (SERS) | |
Liu et al. | Ultrasensitive and facile detection of multiple trace antibiotics with magnetic nanoparticles and core-shell nanostar SERS nanotags | |
JP6960696B2 (ja) | 磁性−光学複合ナノ構造体 | |
Wei et al. | Polymer microbead-based surface enhanced Raman scattering immunoassays | |
Wang et al. | High-sensitivity biosensor based on SERS integrated with dendrimer-assisted boronic acid-functionalized magnetic nanoparticles for IL-6 detection in human serum | |
Cui et al. | Bulk phase-encoded gold nanoparticles: the fourth-generation surface-enhanced Raman scattering tag for Hg2+ ion detection | |
JP2010175327A (ja) | 金属ナノ粒子複合体およびその製造方法、バイオチップおよびその製造方法 | |
AU2011254092A1 (en) | Surface enhanced spectroscopy-active composite nanoparticles and their application in analysis and diagnosis | |
Abdul-Moqueet | A Study of Synthesis and Characterization of Gold Bipyramid Nanoparticle Bioconjugates | |
Azhar | Spectroscopic imaging of multiplex bioassays encoded by raman and SERS Tags | |
Bedford | Gold surface nanostructuring for separation and sensing of biomolecules | |
Mohammed | Harnessing the plasmonic properties of gold nanoparticles: functionalization strategies coupled with novel spectroscopic tools | |
Li | Enabling Tools for Disease Diagnosis, Imaging and Intervention | |
Soh | Development of novel biosensing and diagnostic platforms using nanoparticle complexes | |
Huang | Development of nanoparticle applications in cell imaging, bioassay and reactive oxygen species detection based on surface-enhanced raman spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1106579 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BECTON DICKINSON CO. Free format text: FORMER OWNER: AONYCA CO.,LTD. Effective date: 20090403 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090403 Address after: new jersey Applicant after: Becton Dickinson and Co. Address before: American California Applicant before: Oxonica Inc. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070815 |